A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of Debio 1453P in Healthy Adults
Latest Information Update: 04 Oct 2025
At a glance
- Drugs Debio 1453 (Primary)
- Indications Gonorrhoea; Neisseria infections
- Focus Adverse reactions; First in man
- Sponsors Debiopharm; Debiopharm Group
Most Recent Events
- 26 Aug 2025 According to Debiopharm media release, the first healthy volunteer has been dosed in this trial.
- 08 Aug 2025 Status changed from not yet recruiting to recruiting.
- 25 Jun 2025 Status changed from planning to not yet recruiting.